SC
TEVA icon

SummitTX Capital’s Teva Pharmaceuticals TEVA Stock Holding History

SummitTX Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,956
Closed -$342K – 965
2025
Q4 		$342K Buy
+10,956
New +$270K 0.01% 583
2025
Q2 		– Sell
-65,492
Closed -$1.01M – 1003
2025
Q1 		$1.01M Buy
+65,492
New +$1.17M 0.04% 404

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SummitTX Capital's TEVA Position: Q1 2026 in Review

SummitTX Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 10,956 shares — an estimated $342K sold.

SummitTX Capital first reported a position in TEVA in Q1 2025 and held it in 2 quarters. The position peaked at $1.01M in Q1 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • SummitTX Capital reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SummitTX Capital sold 10,956 Teva Pharmaceuticals shares in Q1 2026, an estimated $342K.
  • SummitTX Capital first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • SummitTX Capital's Teva Pharmaceuticals position peaked at $1.01M in Q1 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.